Having trouble accessing articles? Reset your cache.

Labopharm, Paladin deal

Paladin will acquire Labopharm for C$0.29 per share in cash, or C$20.4 million ($20.7 million) based on 71.6 million shares outstanding at Aug. 2. The price is a 68% premium to Labopharm's close of C$0.17 on Aug. 16,

Read the full 386 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers